Human Tissue Engineering
This article was originally published in SRA
Executive Summary
Marketing authorisation procedures to be harmonised
You may also be interested in...
Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand
Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
No Eudamed, No Problem! Latest Guidance Explains Alternatives While Database Is Built
Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.
David Now Goliath? Made In China PD-1s Sought After By Multinationals
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: